97 results
6-K
EX-99.2
SCNI
Scinai Immunotherapeutics Ltd
4 Jan 24
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4:37pm
agent fees and offering expenses. The company intends to use the net proceeds from the offering for general working capital, research and development
6-K
EX-99.1
SCNI
Scinai Immunotherapeutics Ltd
4 Jan 24
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
4:37pm
, its research and development activities, including the contemplated in-vivo and toxicology studies and a clinical trial, the risk that Scinai
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
9:58am
the offering for general working capital, research and development, and general corporate purposes.
The new warrants described above were offered in a private … to satisfaction of customary closing conditions. The Company expects to use the net proceeds from these transactions for general working capital, research
424B3
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Prospectus supplement
9:57am
intends to use the net proceeds from the offering for general working capital, research and development, and general corporate purposes.
The new … these transactions for general working capital, research and development, and general corporate purposes.
The resale or the issuance of the ADSs, as applicable
6-K
SCNI
Scinai Immunotherapeutics Ltd
2 Jan 24
Report of Foreign Private Issuer
9:26am
closing conditions. The Company expects to use the net proceeds from these transactions for general working capital, research and development
6-K
EX-99.1
99s7a 1ri
2 Jan 24
Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
9:24am
6-K
EX-99.1
o6k6n
7 Nov 23
Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit
6:09am
6-K
EX-99.1
k1x1k3nh6s
2 Nov 23
Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update
1:21pm
F-1
28jz5 tqmxmcry
30 Oct 23
Registration statement (foreign)
4:59pm
6-K
EX-99.1
tfmm6kwy5aj
20 Sep 23
Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering
6:08am
6-K
EX-1.5
46nuwxw96y3toepcyz
19 Sep 23
Report of Foreign Private Issuer
3:06pm
424B5
gxbzqe1rfuxpj4ctp5
19 Sep 23
Prospectus supplement for primary offering
10:03am
424B2
4ujc67g4n87
28 Aug 23
Prospectus for primary offering
4:01pm
F-3
5vge4dfmttw9h54cqu
18 Aug 23
Shelf registration (foreign)
4:16pm
6-K/A
EX-99.1
aknp1hk
18 Aug 23
Current report (foreign) (amended)
10:07am
6-K/A
EX-99.2
rpjpx3b1ft epjquk
14 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
6:08am
6-K/A
EX-99.1
48rhs0ixq
14 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
6:08am
6-K
EX-99.1
4dnhvp88o976d31
11 Aug 23
BiondVax Reports Second Quarter Financial Results and Provides Business Update
9:44am
10-Q
f1qck9e8
15 May 23
Quarterly report
4:49pm
10-K
sv2ta
17 Apr 23
Annual report
4:06pm